Colorectal cancer (CRC), one of the common malignant cancers in the world, is caused by accumulated alterations of genetic and epigenetic factors over a long period of time. Along with that protein-coding genes being identified as oncogenes or tumor suppressors in CRC, a number of lncRNAs have also been found to be associated with CRC. Considering the important regulatory role of lncRNAs, the first goal of this study was to identify CRC-associated lncRNAs from a public database. One such lncRNA, LINC00472, was verified to be downregulated in CRC cell lines and cancer tissues compared with adjacent tissues. In addition, the down-regulation of LINC00472 seemed to be caused by DNA hypermethylation at its promoter region. Furthermore, the expression of LINC00472 and DNA methylation of promoter were significantly correlated with clinicopathological features. And DNA hypermethylation of LINC00472 may serve as a better diagnostic biomarker than its expression for CRC. Finally, we predicted the functions of LINC00472 and constructed a regulatory network and found LINC00472 may be involved in cell cycle and cell proliferation processes. Our results may provide a clue to further research into the function and regulatory mechanism of LINC00472 in CRC.
Methods: A retrospective multicenter chart review of 604 patients with NPC who underwent CCRT from May 2005 to November 2014 was conducted (265 in the PEG group, and 339 in the non-PEG group). Baseline characteristics, weight loss outcome and treatment tolerance were examined and compared between the two groups. Risk factors of more than 10% weight loss during CCRT were assessed by multivariate analysis. Results: We found significantly more T3-T4 tumors (P ¼ 0.03), cisplatin-based regimen (P ¼ 0.01), and less body weight before CCRT (P ¼ 0.04) in the PEG group. Seventy-seven percent of patients in PEG group completed the planned cycles of chemotherapy, whereas only 48% of patients in the non-PEG group did (P < 0.0001). Moreover, lower percentage of weight loss during CCRT detected in the PEG group as compared to the non-PEG group, 8.9þ/-8.0 kilograms (kgs) and 12.5þ/-8.6 kgs, respectively (P < 0.0001). Multivariate analysis showed that obese patients (body mass index (BMI) > 25) (P < 0.0001), carboplatin-based regimen (P < 0.0001), 3-weekly chemotherapy (P ¼ 0.01), and non-prophylactic PEG (P < 0.0001) were significantly related to 10% weight loss during CCRT. Conclusions: Prophylactic PEG is strongly recommended for patients with NPC undergoing CCRT. Significant weight loss during CCRT should be cautiously aware for patients with obesity, receiving carboplatin or 3-weekly chemotherapy regimen and those without prophylactic PEG, hence intensive nutritional supplement is highly suggested for these groups of patients.
Background: Pathologic complete response (pCR) is known to be a predictive marker for favorable outcome after neoadjuvant treatment in HER2 positive (þ) breast cancer. Our aim was to investigate the association between hormone receptor (HR) or tumorinfiltrating lymphocytes (TILs) and pCR in HER2 (þ) breast cancer treated with dual anti-HER2 therapy. Methods: Ninety-four patients with HER2 (þ) breast cancer who received neoadjuvant treatment with docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP) were included in this retrospective analysis. Associations between TILs and pCR were assessed in the overall and hormone receptor (HR) positive (þ) and HR negative (-) populations. We classified subgroups with a cutoff value of stromal TILs (20% TILs vs > 20% TILs) based on ROC curves. Results: Of the 94 cases, 54 (57.4%) tumors achieved pCR (ypT0/is N0) and median TILs was 17.07% [13.81-20.65]. In analysis of hormone receptor, pCR was 51.0% (n ¼ 26/51) in HR (þ) group and 65.1% (n ¼ 28/43) in HR (-) group (p ¼ 0.167). The pCR rate was higher in the high TILs group than in the low TILs group (74.1% vs 51.4%, p ¼ 0.038). In HR (-) group, high TILs and low TILs achieved 90% (n ¼ 9/10) and 57.6% (n ¼ 19/33) of pCR, respectively. In HR (þ), pCR rates of high TILs and low TILs subgroups were 64.7% (n ¼ 11/17) and 41.7% (n ¼ 15/34). Conclusions: In HER2 (þ) breast cancer, HR (-) and high TILs showed higher pCR compared with HR(þ) and low TILs. TILs might be a predictive marker for the treatment response to neoadjuvant dual anti HER2 based chemotherapy. Further investigation in a larger cohort of samples is needed to validate these results. Legal entity responsible for the study: Asan Medical Center. Funding: Has not received any funding.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.